About ACCRUFeR

ACCRUFeR® (ferric maltol) is an FDA-approved oral iron treatment for adults and children 10 years of age and older with iron deficiency.2

Uniquely formulated with a MALTOL SHIELDTM

ACCRUFeR is a stable complex of ferric iron (Fe3+) and maltol, a naturally occurring sugar derivative.2 Unlike iron salts, this iron-sugar derivative complex stays intact in the stomach, dissociating when it reaches the duodenum.2

Why the MALTOL SHIELDTM Matters

Intolerable GI side effects can be a barrier to staying on oral iron replacement therapy.30 ACCRUFeR's MALTOL SHIELDTM makes the difference:

MALTOL SHIELD(TM) closed: Protects iron from oxidizing in the stomach MALTOL SHIELD (TM) opened: Releases iron only when ready for absorption in the small intestine Unused ACCRUFeR excreted: Stays protected, helping patients avoid free iron and irritation

It allows iron in ACCRUFeR to remain bioavailable until it reaches the duodenum, where it can be efficiently absorbed.2,3

It reduces the likelihood of reactive oxygen species (ROS) formation, minimizing the risk for GI side effects and irritation or damage to the intestinal lining.2-4

In clinical studies, 4.6% of patients taking ACCRUFeR (n=175) discontinued treatment due to adverse gastrointestinal reactions, compared with 2.5% of patients taking a placebo (n=120).2,7

Since the iron and maltol remain chelated until absorption, there is less free iron in the gut, lessening the risk for added bowel inflammation.2,3

In clinical studies, a 97% median overall treatment compliance was seen during the 12-week randomized period and during the 52-week open label extension.1

Watch ACCRUFeR's Mechanism of Action:

Icon of figure with shield over stomach
ACCRUFeR is now indicated for children 10 years of age and older

The safety and efficacy profile in ACCRUFeR’s pediatrics study was consistent with that observed in adults with iron deficiency or iron deficiency anemia.2 

Established Safety and Efficacy

ACCRUFeR is backed by a robust clinical profile. It has demonstrated both short- and long-term efficacy across three pivotal clinical studies.

Access and Affordability

We’re committed to making ACCRUFeR affordable. Your patients have more than one way to save. 

References:
1. Schmidt C, Ahmad T, Tulassay Z, et al. Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a phase 3 study. Aliment Pharmacol Ther. 2016;44(3):259-270. doi:10.1111/apt.13665
2. ACCRUFeR® full prescribing information. Shield Therapeutics, 2025.
3. Stallmach A, Büning C. Ferric maltol (ST10): a novel oral iron supplement for the treatment of iron deficiency anemia in inflammatory bowel disease. Expert Opin Pharmacother. 2015;16:2859-2867.
4. European Medicines Agency. Accessed March 17, 2021. https://www.ema.europa.eu/en/documents/variation-report/feraccru-h-c-2733-ii-0010-epar-assessment-report-variation_en.pdf
7. Data on file. Shield Therapeutics Inc. 2019.
30. DeLoughery TG. Safety of oral and intravenous iron. Acta Haematol. 2019;142(1):8-12. doi:10.1159/000496966.